Has crizotinib significantly impacted non-small-cell lung cancer therapy?

Figures & data

Figure 1. Activity (Overall response rate, according to RECIST 1.1 Criteria) of crizotinib for oncogene-addicted NSCLC (studies conducted exclusively in Asian patients are excluded)

ORR: overall response rate, according to RECIST 1.1 Criteria; N.: number; mut.: mutation; amp.: amplification; Ph.: Phase; NSCLC: nonsmall-cell lung cancer.

Table 1. Prospective trials using crizotinib for oncogene-addicted NSCLC (studies conducted exclusively in Asian patients are excluded)

Trial	No.	Treatment line	Drugs	RR (%)	PFS		OS
					mPFS (mo.)	95% CI	mOS (mo.)	95% CI
ALK rearranged NSCLC
PROFILE 1001 (Ph. I expansion cohort)	143	Any line	CRZ	61%	9.7	7.7–12.8	NR	-
PROFILE 1005 (Ph. II)	255	≥ 1line	CRZ	54%	8.4	7.1–9.7	21.8	19.4–24
PROFILE 1007 (Ph. III)	347	≥ 1line	CRZ vs Pem or DOC	65%	7.7	6.0–8.8	20.3	18.1 – NR
Profile 1014 (Ph. III)	343	1 line	CRZ vs PL+Pem	74%	10.9	8.3–13.9	NR
ROS-1 rearranged NSCLC
PROFILE 1001 (Ph. I expansion cohort)	53	Any line	CRZ	53%	19.3	15.2–39.1	51.4	29.3 – NR
EUCROSS (Ph. II)	34	Any line	CRZ	70%	20.0	10.1 – NR	NR	-
AcSe Study (Ph. II)	37	Any line	CRZ	69.4%	5.5	4.2–9.1	17.2	6.8–32.8
METROS (Ph. II)	26	≥ 1 line	CRZ	65%	22.8	15.2–30.3	NR	-
MET addicted NSCLC
PROFILE 1001 (MET-Exon 14 mut.)	65	Any line	CRZ	32%	7.3	6.4–12.7	-	-
METROS (MET- Exon 14 mut./amp.)	26	≥ 1 line	CRZ	27%	4.4	3.0 ‒ 5.8	5.4	4.2–6.5
AcSe Study (MET- Exon 14 mut.)	28	Any line	CRZ	36%	2.4	1.6–5.9	8.1	4.1–12.7
AcSe Study (MET-amp.)	25	Any line	CRZ	32%	3.2	1.9–3.7	7.7	4.6–15.7

No.: number; RR: response rate; m: median; mo: months; CI; confidence interval; PFS: progression free survival; OS: overall survival; CRZ: crizotinb; NR: not reported; PL: platinum agents; Pem: pemetrexed; DOC: docetaxel; Ph.: phase; NSCLC: nonsmall-cell lung cancer; mut.: mutation; amp.: amplification.